Journal of Crystallization Process and Technology
Vol.4 No.1(2014), Paper ID 41735, 4
pages
DOI:10.4236/jcpt.2014.41004
The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound
Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
Copyright © 2014 Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Y. Huang, Z. Tan, L. Luo, H. Yang, C. Tong, W. Chen, T. Huang and R. Liu, "The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound,"
Journal of Crystallization Process and Technology, Vol. 4 No. 1, 2014, pp. 27-30. doi:
10.4236/jcpt.2014.41004.